BiomEdit Advances BE-101 Poultry Biologic Toward USDA Conditional Licensure

New updates have been reported about BiomEdit.

BiomEdit has entered the final regulatory phase for its lead product, BE-101, by starting a pivotal field safety trial using pre-licensing commercial manufacturing batches in U.S. broiler complexes. Two of three required field sites are already underway, and, pending successful completion of safety assessments and USDA Center for Veterinary Biologics review of trial data and batch testing, the company targets conditional licensure in Q3 2026 with a commercial launch aligned for early Q4 2026.

BE-101, a probiotic vectored antibody biologic designed to neutralize Clostridium perfringens toxins that drive necrotic enteritis, addresses a disease estimated to cost the global broiler industry about $6 billion annually. A recent study in an npj Biofilms and Microbiomes journal reported statistically significant gains in feed conversion and body weight, reduced NE mortality, and improved gut health in sub-clinical challenge conditions, reinforcing the product’s potential production and economic impact for poultry producers as BiomEdit moves toward market entry.